

# The Journal of PHARMACOLOGY

## And Experimental Therapeutics

A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2023

Vol. 385, No. 3

### Contents

#### VIEWPOINT

- Bath Salts to Therapies: Can Separation of Adverse and Therapeutic Effects of Substituted Cathinones Lead to a Medication for Psychostimulant Use Disorder? 159  
*Ellen M. Unterwald and Scott M. Rawls*
- Neurochemical and Cardiovascular Effects of 4-Chloro Ring-Substituted Synthetic Cathinones in Rats 162  
*Michael R. Chojnacki, Eric B. Thorndike, John S. Partilla, Kenner C. Rice, Charles W. Schindler, and Michael H. Baumann*

#### BEHAVIORAL PHARMACOLOGY

- Assessment of Abuse-Related Discriminative Stimulus Effects of Nicotine Aerosol in Rodents 171  
*Yasmin Alkhlaif and Keith L. Shelton*
- Pharmacokinetic and Pharmacodynamic Consequences of Cytochrome P450 3A Inhibition on Mitragynine Metabolism in Rats 180  
*Shyam H. Kamble, Samuel Obeng, Francisco León, Luis F. Restrepo, Tamara I. King, Erin C. Berthold, Siva Rama Raju Kanumuri, Lea R. Gamez-Jimenez, Victoria L.C. Pallares, Avi Patel, Nicholas P. Ho, Aidan Hampson, Christopher R. McCurdy, Lance R. McMahon, Jenny L. Wilkerson, Abhisheak Sharma, and Takato Hiranita*

#### DRUG DISCOVERY AND TRANSLATIONAL MEDICINE

- TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy 193  
*Takashi Ishikawa, Hiroe Hara, Ayumi Kawano, Kimio Tohyama, Yuichi Kajita, Yuhei Miyanoohana, Tatsuki Koike, and Haruhide Kimura*
- In Vivo Pharmacokinetic and Pharmacodynamic Properties of the Antiarrhythmic Molecule *ent*-Verticilide 205  
*Daniel J. Blackwell, Abigail N. Smith, Tri Do, Aaron Gochman, Jeffrey Schmeckpeper, Corey R. Hopkins, Wendell S. Akers, Jeffrey N. Johnston, and Bjorn C. Knollmann*

#### ENDOCRINE AND DIABETES

- BI-Y, an Neupilin-1 Antagonist, Enhances Revascularization and Prevents Vascular Endothelial Growth Factor-A Induced Retinal Hyperpermeability in Rodent Models of Retinopathies 214  
*Leo Thomas, Sarah Low, Gale Hansen, Remko A. Bakker, and Nina Zippel*

#### ERRATUM

- Correction to "Cannabinoid Tolerance in S426A/S430A x  $\beta$ -Arrestin 2 Knockout Double-Mutant Mice" 222

Supplemental material is available at [jpet.aspetjournals.org](http://jpet.aspetjournals.org).

*About the cover:* BI-Y antagonizes the biological effects of Nrp-1, thus also Sema3A and partially VEGF, promoting revascularization and reducing hyperpermeability. See the article by Thomas et al. ([dx.doi.org/10.1124/jpet.122.001473](https://doi.org/10.1124/jpet.122.001473)).